Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
New multidrug-resistant tuberculosis drug approved
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Nov 3, 2014 15:03:55
Otsuka Korea got marketing approval for Deltyba to treat pulmonary multidrug-resistant tuberculosis, the Ministry of Food and Drug Safety said on October 30.

Deltyba, generically known as delamanid, works by interfering with the metabolism of the Mycobacterium tuberculosis cell walls.

The approval follows a review of data from clinical trial results in 9 countries. Those trials demonstrated that patients treated with delamanid, 100 mg twice daily, combined with an optimized background regimen (OBR) experienced a statistically significant increase in sputum culture conversion after 2 months (45.4% of patients) compared with those receiving placebo plus OBR (29.6% of patients). Sputum culture conversion indicates when a patient is no longer infectious.

Janssen Korea rolled out Sirturo to treat pulmonary multidrug-resistant tuberculosis in March 2014.

South Korea has the most tuberculosis patients among OECD countries. It is known that 1,200 patients in South Korea have multi-drug resistant tuberculoris.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com